



**Peptide Receptor Radionuclide Treatment and (131)I-MIBG
in the management of patients with metastatic/progressive
Pheochromocytomas and Paragangliomas.**

| | |
|-------------------------------|---|
| Journal: | <i>Journal of Surgical Oncology</i> |
| Manuscript ID | JSO-2016-0911.R2 |
| Wiley - Manuscript type: | Research Article |
| Date Submitted by the Author: | 11-Dec-2016 |
| Complete List of Authors: | Nastos, Konstantinos; Royal Free Hospital, ENETS Centre of Excellence Neuroendocrine Tumour Unit Cheung, Vincent; Royal Free Hospital, ENETS Centre of Excellence Neuroendocrine Tumour Unit Toumpanakis, Christos; Royal Free Hospital, ENETS Centre of Excellence Neuroendocrine Tumour Unit Navalkisoor, Shaunak; Royal Free Hospital, ENETS Centre of Excellence Neuroendocrine Tumour Unit Quigley, Anne-Marie; Royal Free Hospital, ENETS Centre of Excellence Neuroendocrine Tumour Unit Caplin, Martyn; Royal Free Hospital, ENETS Centre of Excellence Neuroendocrine Tumour Unit Khoo, Bernard; Royal Free Hospital, ENETS Centre of Excellence Neuroendocrine Tumour Unit |
| Key Words: | radionuclide therapy, (131)I-MIBG, paraganglioma, pheochromocytoma, peptide receptor radionuclide treatment |
| | |

SCHOLARONE™
Manuscripts

Title:

Peptide Receptor Radionuclide Treatment and (131)I-MIBG in the management of patients with metastatic/progressive Pheochromocytomas and Paragangliomas.

Authors and Affiliations:

Konstantinos Nastos PhD¹, Vincent T.F. Cheung MD¹, Christos Toumpanakis PhD¹, Shaunak Navalkissoor PhD², Anne-Marie Quigley MD², Martyn Caplin PhD¹, Bernard Khoo PhD^{1,3}.

¹ENETS Centre of Excellence Neuroendocrine Tumour Unit, Royal Free London NHS Foundation Trust, London, NW3 2QG, UK

²Department of Nuclear Medicine, Royal Free London NHS Foundation Trust, London, NW3 2QG, UK.

³Department of Endocrinology, Royal Free London NHS Foundation Trust, London, NW3 2QG, UK.

Short running title:

Radionuclide therapy of advanced PGL/PCC

Conflict of interest statement:

Funding: This study was self funded by the department.

Conflict of interest: There is no conflict of interest by any of the authors.

Corresponding and First author: Constantinos Nastos, M.D., Ph.D.

ENETS Centre of Excellence Neuroendocrine Tumour Unit, Royal Free Hospital, Pond Street, London, UK. Tel: +44-7474277140

email: konstantinos.nastos@nhs.net, kosnastos@yahoo.gr

Synopsis:

Radionuclide treatment has been shown to be quite effective in the management of advanced paragangliomas and pheochromocytomas. Apart from I(131)-MIBG which has been used in the past, recently, peptide receptor radionuclide treatment (PRRT) has been

1
2
3 shown to be effective in the management of these tumors. We present series of patients
4
5
6 showing their response to these treatments.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

Abstract

Background and objectives: Radionuclide therapy has been used to treat patients with progressive/metastatic paragangliomas (PGLs) and pheochromocytomas (PCCs). The aim of the present study is to retrospectively compare the therapeutic outcomes of these modalities in patients with progressive/metastatic PCCs and PGLs.

Methods: Patients with progressive/metastatic PGLs and PCCs that were subjected to radionuclide treatment in our department were retrieved from our department's database for the period 1998-2013. Overall survival (OS), progression free survival (PFS), event free survival (EFS) and response to treatment were calculated. Treatment toxicity was documented.

Results: Twenty two patients with progressive/metastatic PGLs or PCCs were treated with either (131)I-MIBG, (90)Y-DOTATATE or (177)Lu-DOTATATE. A total of 30 treatments were administered (16 treatments with (131)I-MIBG, 2 with (177)Lu-DOTATATE and 12 with (90)Y-DOTATATE. Patients treated with PRRT had increased PFS and response to treatment compared to (131)I-MIBG treated patients ($p < 0.05$). However, difference in OS was non significant ($p = 0.09$). There was no difference in major toxicities between groups. When comparing only patients with PGLs, OS, PFS, EFS and response to treatment were significantly higher in the PRRT treatment group.

Conclusion: PRRT treatment offers increased OS, PFS, EFS and response to treatment compared to (131)I-MIBG therapy in patients with progressive/malignant PGLs.

1
2
3 **Keywords:** radionuclide therapy, (131)I-MIBG, peptide receptor radionuclide treatment,
4
5
6 phaeochromocytoma, paraganglioma,
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

Introduction

Phaeochromocytomas (PCC) and paragangliomas (PGL) are tumors of chromaffin cells that often produce and secrete catecholamines and their metabolites. PCC occur within the adrenal medulla and PGL present as tumors of the extra-adrenal sympathetic nervous system, occurring in the head and neck, chest, abdomen, or pelvis [1]. These tumors can present either as benign, in the majority of the cases, or may be malignant.

There are currently no established criteria for establishing PCC/PGL as malignant apart from the presence of metastases at diagnosis [2]. In cases where metastases are found, surgery is usually of limited therapeutic value and other therapeutic modalities have been proposed. These include chemotherapy, external radiotherapy, radiofrequency ablation therapy, tyrosine kinase receptor inhibitors and radionuclide therapy [2-6].

(131)I-metaiodobenzylguanidine (MIBG) is a frequently used treatment for advanced neuroendocrine tumors, leading to symptomatic control, stabilization of disease progression and increased overall survival [7]. Peptide Receptor Radionuclide treatment (PRRT) with radiolabeled somatostatin analogues have also been used in the treatment of neuroendocrine tumors. However, data on PRRT use in metastatic PCCs and PGLs are limited. There are a few reports for the treatment of these patients with PRRT, and although this therapy seems effective, it is not reported to be as effective as in other subtypes of neuroendocrine tumors [8-10].

To date, there is no study comparing (131)I-MIBG treatment and PRRT in the management of patients with progressive PCCs and PGLs. The aim of the present study is to retrospectively compare MIBG and PRRT treatment in patients with

1
2
3 metastatic/progressive PCCs and PGLs, in terms of overall survival, progression free
4 survival, event free survival, response to treatment, and toxicity.
5
6
7
8
9

10 11 12 **Materials and Methods**

13 14 15 *Population*

16
17
18 This was a retrospective study of the patients with locally advanced /metastatic
19 progressive PGLs and PCCs treated in our department during the period 1998-2013. All
20 patients were characterized as “metastatic” either during follow-up after initial surgery, or
21 when metastases were present at tumor diagnosis.
22
23
24
25
26
27

28
29 The decision for commencement of radionuclide therapy was made in the Neuroendocrine
30 Tumour Multi-Disciplinary Team meeting and was based on either disease progression
31 and/or failure to control symptoms of catecholamine hypersecretion. Patients were
32 allocated to either (131)I-MIBG or PRRT treatment, according to their respective tumor
33 avidities for (123)I-MIBG versus somatostatin receptor agonist tracers, either (111)In-
34 diethylenetriaminepentaacetic acid (DTPA)-Octreotide or (68)Ga- tetraazacyclododecane
35 tetraacetic acid octreotate (DOTATATE). Patients that had metastatic
36 pheochromocytomas were scanned for (123)I- MIBG avidity and then scanned for
37 somatostatin analogue peptide avidity if there was no avidity or poor avidity to (123)I-
38 MIBG. Patients with metastatic paragangliomas were checked for avidity to (123)I-
39 MIBG and when negative for avidity to somatostatin receptor agonist tracers. In view of
40 this patients in our series were not routinely scanned for both modalities throughout the
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 entire study period. However, during the years of the study period imaging with
4
5 somatostatin receptor agonist tracers has increased in our department as a result of the
6
7
8 increased avidity that has been shown in patients with PGLs.
9

10 Patients with non-progressive and symptomatically controlled disease, surgically
11
12 treatable primary or metastatic disease, as well as patients with renal failure or bone
13
14 marrow disease were excluded from radionuclide treatment.
15

16
17 Patient age, sex, tumor type, tumor location, genetic background, the presence of
18
19 metastasis on diagnosis, the operability, the extent of metastatic disease, the functionality
20
21 of the tumor and the administration of additional therapies were recorded.
22
23

24 As this was a retrospective audit of practice, research ethical approval was not required.
25
26
27
28

29 *Radionuclide Therapy Protocol*

30 **(131)I-MIBG**

31
32 All patients had a pre-therapy (123)I-MIBG scan to assess appropriate uptake of tracer in
33
34 the sites of known disease. The administered activity of (123)I-MIBG was 220 MBq with
35
36 scans performed on a dual-head gamma camera using a low-energy high-resolution
37
38 collimator 24 h after injection.
39
40
41
42

43 Treatment was administered in a shielded side-room on the oncology ward. Patients
44
45 underwent thyroid blockade with oral potassium iodide prior to treatment, starting on the
46
47 day of the therapy and continued for a further 4 days after therapy. Ondansetron 8 mg
48
49 orally was also given 30 min before the (131)I-MIBG to minimize nausea. Standard
50
51 activity varied over the years. In patients treated after the year 2000, the standard activity
52
53 administered was of 5.5 or 7.4 GBq of (131)I-MIBG (GE Healthcare, Amersham,
54
55
56
57
58
59
60

1
2
3 Buckinghamshire, UK) in two vials (5.5 GBq) or three vials (7.4 GBq). The standard
4
5 protocol involved three cycles of (131I)-MIBG therapies with intervals of 10–12 weeks
6
7 between each treatment. Fewer than three cycles were administered if there was any
8
9 evidence of significant toxicity. Patients before 2000 were treated using two different
10
11 regimes. Those with fast-growing tumours and significant symptoms were treated with
12
13 three infusions of 131I-MIBG, given at 10- week to 12-week intervals. If there was
14
15 evidence of response, the patients were then maintained on 6- monthly treatments. In
16
17 those patients with more slowly growing disease, 6-monthly treatments were used from
18
19 the outset.

20
21 Treatment was administered over approximately 40 min using a semi-automated delivery
22
23 system (GE Healthcare, Amersham, Buckinghamshire, UK), with 90% of activity passing
24
25 from the delivery system to the patient. Cardiovascular monitoring was routinely used
26
27 during administration. Patients were closely observed from behind a lead shield during
28
29 the administration. Patients were monitored by the hospital radiation safety group and
30
31 discharged when their dose rate at 1 m had fallen to ≤ 600 MBq. Two to three days after
32
33 treatment, a post-therapy whole-body scan was obtained on a dual-head gamma camera
34
35 using a high energy general purpose collimator. This was performed to assess the
36
37 biodistribution of the tracer.

46 **PRRT**

47
48 Treatment was administered in a shielded side-room on the oncology ward. Ondansetron
49
50 8 mg was injected intravenously and an infusion of amino acids containing lysine 25g
51
52 and arginine 25g in 2 L 0.9% NaCl was started 30 minutes before the administration of
53
54 the radiopharmaceutical and lasted 4 hours. The radiopharmaceutical [either (90)Y-

1
2
3 DOTATATE or (177)Lu-DOTATATE] was co-administered via a second pump system.
4
5 Cycle activities given were 3.2 GBq for Y-90 DOTATATE and 7.4 GBq for Lu-177
6
7 DOTATATE, injected over 30 minutes. The standard protocol involved three to four
8
9 cycles of therapies with intervals of 10–12 weeks between each treatment. Fewer cycles
10
11 were administered if there was any evidence of significant toxicity.
12
13
14
15
16
17

18 *Follow-Up*

19
20 Patients' symptoms and adverse effects were evaluated after each cycle and overall 3
21
22 months following the completion of treatment courses. Routine haematology, liver,
23
24 renal, and thyroid function tests, as well as tumour markers were performed before each
25
26 therapy, as well as at follow-up visits. Follow up was discontinued only if the patient died
27
28 or were assigned to palliative care, when only information concerning the patients' status
29
30 were recorded.
31
32
33

34 Although biochemical and symptomatic response was evaluated with blood
35
36 investigations and quality of life questionnaires (EORTC QLQ – GI.NET21), this was not
37
38 done consistently and per protocol and as a result data were not eligible for retrospective
39
40 collection and analysis.
41
42

43 Patients underwent restaging cross-sectional imaging (CT or MRI) between 6 weeks and
44
45 3 months after the completion of treatment courses and then every 4-6 months. Tumor
46
47 response to treatment was evaluated retrospectively according to the RECIST 1.1 criteria.
48
49

50 All imaging were reviewed by an experienced radiologist.
51

52 Progression free survival was defined as the interval between the first radionuclide
53
54 treatment and the radiological progression of the disease, or death related to the disease.
55
56
57
58
59
60

1
2
3 Time to progression was also calculated and was defined as interval between the first
4 radionuclide treatment and the radiological progression of the disease without taking
5 death into account. Finally, as we did not have any consistent data on quality of life after
6 the treatment, we calculated event free survival, which was defined as the interval
7 between the first radionuclide treatment and any event related to radiological progression,
8 major toxicity, any major disease related event that lead to hospitalization or death. As
9 many patients were subjected to multiple treatments, progression free survival, time to
10 progression, event free survival and response to treatment were calculated individually
11 for every treatment and not per patient. Overall survival was calculated for every patient
12 and was defined as the interval between the first radionuclide treatment and death.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

29 *Treatment toxicity*

30
31 Minor side effects, during or after treatments, were not recorded. Data for major side
32 effects of treatment, in terms of haematological and renal toxicity, were collected. Renal
33 and haematological toxicity were graded, according to the National Cancer Institute
34 Toxicity Criteria.
35
36
37
38
39
40
41
42

43 *Statistical Analysis*

44
45 Results are expressed as mean \pm standard deviation (SD). Comparison between groups
46 was performed using the Chi-Square test for qualitative data and the unpaired t-test for
47 quantitative data. Overall Kaplan–Meier survival curves, progression-free Kaplan–Meier
48 survival curves, time to progression curves and event free survival curves were generated
49 for each group and compared with a log-rank test for proportional hazards and the
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Breslow test if differences were depicted early in the follow up period. A p value smaller than 0.05 was considered as significant.

For Peer Review

Results

During the period 1998-2013 we found 22 patients with progressive metastatic paragangliomas or pheochromocytomas that were referred for radionuclide therapy with either (131)I-MIBG, (90)Y-DOTATATE and (177)Lu-DOTATATE. The mean age at diagnosis was 46.9 ± 15 years. Patient characteristics are summarized in TABLE 1.

From the 22 patients receiving radionuclide treatment 8 patients received treatment with (90)Y-DOTATATE, 1 patient treatment with (177)Lu-DOTATATE, 11 patients treatment with (131)I-MIBG and 2 patients received a combination of the above treatments. A total of 30 treatments were administered in these patients. Analytically, these consisted of 16 treatments with (131)I-MIBG, 2 treatments with (177)Lu-DOTATATE and 12 treatment cycles of (90)Y-DOTATATE. The seven patients with PCCs were subjected to 9 treatments, 8 of which were with (131)I-MIBG and one with (90)Y-DOTATATE. The 15 with PGLs were subjected to 21 treatments, from which 13 were with PRRT and 8 were with (131)I-MIBG. The above data, cumulative dosage, treatment cycles and total number of treatments are summarized in TABLE 2.

Patients were followed up continuously in our departments' outpatient clinic. The follow-up period ranged from 6 to 122 months (mean 38.7 months) for patients that eventually died and 2 to 134 months (mean 56.4 months) for patients that were alive at the end of the study period. We had no patients lost in follow-up. Overall survival was compared between patients that received (131)I-MIBG or PRRT treatment, and thereafter between patients treated with (131)I-MIBG and (90)Y-DOTATATE. Only two patients received (177)Lu-DOTATATE, thus making the addition of an additional group not applicable. Overall survival was not different when comparing treatments with (131)I-MIBG versus

1
2
3 PRRT, or (131)I-MIBG versus (90)Y-DOTATATE ($p=0.09$ and $p=0.08$ respectively).
4
5 Further stratification of the two treatment groups according to tumor type was made. All
6
7 patients with progressive/metastatic PCCs were treated with (131)I-MIBG or a
8
9 combination of (131)I-MIBG with PRRT (as per imaging avidity protocol) and as a result
10
11 no comparison was made. Patients with progressive/metastatic PGLs had a longer overall
12
13 survival when treated with PRRT or (90)Y-DOTATATE compared to (131)I-MIBG
14
15 ($p=0.01$).
16
17

18
19 Progression free survival for all patients was longer in patients treated with (90)Y-
20
21 DOTATATE compared with (131)I-MIBG ($p=0.04$), however, this difference was not
22
23 statistically significant when comparing all PRRT treated patients ($p=0.1$). In patients
24
25 with PGLs, progression free survival was longer after PRRT or (90)Y-DOTATATE
26
27 treatment compared to patients treated with (131)I-MIBG ($p=0.01$ and $p=0.007$,
28
29 respectively). There were no differences in time to progression or event free survival
30
31 between these treatment groups, when including all patients. However, in patients with
32
33 PGLs, event free survival was longer both after (90)Y-DOTATATE ($p=0.02$) or any
34
35 PRRT treatment ($p=0.04$), compared with patients treated with (131)I-MIBG. Data are
36
37 summarized in TABLES 3 and 4 and FIGURE 1 and 2.
38
39
40
41
42

43 Response to treatment, as determined by RECIST 1.1 criteria, was significantly better
44
45 after PRRT, in general, and after (90)Y-DOTATATE treatment compared to (131)I-
46
47 MIBG treated patients ($p=0.013$ and $p=0.021$ respectively). When comparing patients
48
49 with PGLs separately, response to treatment was also higher when comparing either
50
51 PRRT, in general, or (90)Y-DOTATATE treatment specifically with (131)I-MIBG
52
53 treated patients ($p=0.005$ and $p=0.008$, respectively).
54
55
56
57
58
59
60

1
2
3 Six patients (27.2%) developed renal impairment during their follow up. However, not all
4
5 of these toxic events were related to the radionuclide treatment. In one case renal
6
7 impairment was due to ureteric obstruction from the tumor and in another case renal
8
9 impairment was secondary to NSAID treatment after a metastatic fracture. When these
10
11 cases were excluded, only 4 (18.1%) patients developed renal toxicity related to
12
13 radionuclide treatment, of which only 2 (9%) were serious (Grade 3 or 4). One of the
14
15 patients was treated with PRRT, while the other one was treated with a combination of
16
17 (131)I-MIBG and PRRT. Nine (40.9%) patients had haematological complications during
18
19 their follow up, but only 5 cases (22.7%) could be attributed to radionuclide treatment.
20
21 There was no difference in haematological toxicity between patients treated with (131)I-
22
23 MIBG and patients treated with (90)Y-DOTATATE therapy. Both renal and
24
25 haematological side effects are summarized in Table 5.
26
27
28
29
30
31
32
33
34
35
36

37 Discussion

38
39 The management of patients with metastatic PCCs and PGLs can be challenging.
40
41 Although multiple therapeutic modalities exist, including chemotherapy, external beam
42
43 radiation, tyrosine kinase inhibitors and surgery in some cases, radionuclide treatment has
44
45 been shown to be most effective in the treatment of those patients [10-12]. Traditionally,
46
47 (131)I-MIBG has been shown to have a high tracer affinity for these tumors [13]. During
48
49 the last decades, radionuclide imaging with radiolabeled somatostatin analogues has been
50
51 shown to be an alternative option, as well, leading to respective therapeutic interventions
52
53 [8]. (90)Y-(DOTATOC), (90)Y-DOTATATE and (177)Lu-DOTATATE are the main
54
55
56
57
58
59
60

1
2
3 peptide receptor radionuclide treatment used to date [8-10,14]. The literature is scarce in
4
5 studies comparing these two agents in neuroendocrine tumors in general, while there is
6
7 no study to date comparing these treatment modalities in metastatic/progressive
8
9 PCCs/PGLs.
10
11

12
13 In our study, most of the PRRT treatments used (90)Y-DOTATATE, with the exception
14
15 of two patients that received (177)Lu-DOTATATE (one as a monotherapy and one as an
16
17 additional treatment cycle after previous (131)I-MIBG treatment). This was due to the
18
19 fact that (177)Lu-DOTATATE was not available in our department during the entire data
20
21 collection period, and became available after 2011.
22
23

24
25 Patients with metastatic PCCs were treated mainly with (131)I-MIBG. On the contrary,
26
27 patients with metastatic PGLs were treated either with (131)I-MIBG or PRRT, mostly
28
29 with (90)Y-DOTATATE. This can be explained by the fact that patients with PCCs were
30
31 mostly (123)I-MIBG avid. The opposite was true for patients with PGLs, where there
32
33 was increased avidity for somatostatin receptor radionuclide imaging. **During the last
34
35 decades diagnostic imaging strategies have changed significantly for these two tumors.
36
37 Traditionally these tumors were both imaged with MIBG, until a significant percentage
38
39 of PGLs and some PCCs were found to be avid to (111)In- (DTPA)-Octreotide scan
40
41 and even bigger percentage avid to (68)Ga- (DOTATATE) PET. In view of this the
42
43 imaging protocol of these patients in our department has evolved as well during the study
44
45 period.** This is in accordance with the literature [15-18].
46
47
48
49

50
51 Overall survival was not significantly different when comparing (131)I-MIBG and PRRT
52
53 treatments in the entire study population. However, when only patients with PGLs were
54
55 compared, there was a difference in overall survival between the treatment groups. The
56
57
58
59
60

1
2
3 difference in our results when stratifying for tumor type can be interpreted by a difference
4
5 in the efficacy of the two treatment modalities.
6
7

8 The two treatment modalities were also compared in PFS, TTP, EFS and response to
9
10 treatment. Our results show that PRRT seems to be more effective than (131)I-MIBG in
11
12 terms of response to treatment, but with no difference in PFS, TTP and EFS in patients
13
14 with metastatic PGLs and PCCs. However, when comparing only patients treated with
15
16 (90)Y-DOTATATE, they had increased response to treatment, as well as PFS.
17
18

19
20 Very few studies have addressed the effect of PRRT in the management of patients with
21
22 metastatic PGLs and PCCs. Recently, Forrer reported an overall response to treatment in
23
24 22 of 28 (78%) patients, with a PFS ranging from 3 to 43 months [8]. Prasad et al also
25
26 reported the results of PRRT [(90)Y-DOTATATE, (177)Lu-DOTATATE and
27
28 combination] in 20 patients with progressive PGLs and PCCs. They reported an 80% and
29
30 43% overall response rate with (177)Lu-(DOTATATE and (90)Y-DOTATATE
31
32 treatment, respectively. Best results were reported after combination treatment [9].
33
34

35
36 Recently, Puranik et al reported a series of 9 patients with inoperable head and neck
37
38 paragangliomas treated with PRRT. They demonstrated disease stabilization and
39
40 symptomatic relief of these patients after treatment. However, theirs study did not
41
42 concern metastatic disease as only one of the nine patients had distant metastasis [10].
43
44

45
46 In our study, we have shown a response in 11 of 11 (100%) treatments with (90)Y-
47
48 DOTATATE and a mean PFS of 43 months. However, this result should be interpreted
49
50 with caution, as one of the patients in this group had initially presented with a locally
51
52 inoperable and symptomatic PGL, received radionuclide treatment and later developed
53
54 metastases. In addition, in our study, response to treatment was evaluated 6 weeks to 3
55
56
57
58
59
60

1
2
3 months after treatment and according to RECIST 1.1 criteria, as opposed to WHO and
4
5 other criteria used in other studies [7].
6

7
8 Radionuclide treatment with (131)I-MIBG has been better studied in patients with
9
10 progressive/malignant PCCs and PGLs. Recently, Gonias et al reported a phase II
11
12 prospective study of 50 patients with malignant disease that were treated with high dose
13
14 (131) MIBG. In their study, they reported 27% response to treatment and 80% non-
15
16 progressive disease with radiologic criteria after the first treatment. In our study we
17
18 observed 62.5% non- progressive disease after (131)I-MIBG treatment sessions.
19
20 However, in their study they evaluated response rate 3 to 6 months after the treatment, in
21
22 contrast to our study, where the response rate was evaluated 6 to 12 weeks after
23
24 treatment. In addition, in their study, they incorporated patients receiving a higher dose
25
26 protocol for (131)I-MIBG, compared to our study. Fitzgerald et al also reported an initial
27
28 83 % overall response rate after high dose (131)I-MIBG treatment in patients with PGLs
29
30 and PCCs. Some patients showed progression later in their follow up and the overall
31
32 response rate became 66%[1].
33
34
35
36
37

38
39 An interesting finding in our study is that efficacy of treatment seems to be different
40
41 between patients with PCCs and PGLs, suggesting that these two pathologies should
42
43 probably not be treated similarly. PRRT was found to be of no benefit to OS, OFS, EFS
44
45 and TTP compared to (131)I-MIBG when including all the patients in the analysis.
46
47 However, there was a clear benefit in terms of response to treatment. One could argue
48
49 that PCC patients were only treated with (131)I-MIBG or a combination of (131)I-MIBG
50
51 and PRRT and these patients have been reported to have worse prognosis than patients
52
53 with PGLs, thus effecting our results. However, we noted a clear difference in overall
54
55
56
57
58
59
60

1
2
3 survival, PFS, EFS and response to treatment in favor of PRRT when comparing only
4 patients with metastatic PGLs, as opposed to incorporating PCCs in the comparison. A
5
6 similar comparison could not be made for PCC patients due to the retrospective nature of
7
8 the study, as all patients with PCCs were treated with (131)I-MIBG or a combination of
9
10 (131)I-MIBG and PRRT. It is possible that PCCs and PGLs have a different response to
11
12 (131)I-MIBG or PRRT. Chen et al have shown that somatostatin receptor scintigraphy is
13
14 more sensitive than (131)I-MIBG imaging in the detection of extra-adrenal
15
16 phaeochromocytomas using (99m)Tc-HYNIC-TOC as a tracer [15]. In the same time,
17
18 Koopmans et al have reported similar data for the affinity of head and neck
19
20 paragangliomas using (111)In-octreotide vs (123)I-MIBG [16]. In keeping with this, Jalil
21
22 et al has reported a sensitivity of 88% for the detection of unilateral PCCs as opposed to
23
24 64% for extra adrenal tumors using (131)I-MIBG scintigraphy [19]. Bhatia et al have
25
26 published similar results (85% for PCCs and 58% for PGLs) with (123)I-MIBG
27
28 scintigraphy.
29
30
31
32
33
34
35

36 The single most important finding of our study was that patients with metastatic PGLs
37
38 seem to have a better prognosis when receiving PRRT treatment instead of (131)I-MIBG.
39
40 In view of this it seems more rational that these patients be preferentially scanned for
41
42 somatostatin receptor agonist tracer avidity and only when no avidity is found, for
43
44 (123)I-MIBG avidity. However, the same cannot be said for patients with metastatic
45
46 PCCs, direct comparison between the two treatments could not be made in our study.
47
48
49

50 A major limitation of our study includes the retrospective nature of the data collection. In
51
52 addition, the PRRT group included only a small number of patients treated with (177)Lu-
53
54 DOTATATE, since it has only been available in our unit since 2011. In the (131)I-MIBG
55
56
57
58
59
60

1
2
3 treatment group dosage protocols varied during the period studied and as a result, there is
4
5 heterogeneity in the treatment protocol between patients. Our unit's protocols did not
6
7 include high dosage treatments, which has been reported to be quite effective in
8
9 neuroendocrine tumors in general and PGLs/PCCs in particular. Recent data have also
10
11 speculated the role of a combination of these treatment modalities, in order to be able to
12
13 maximize efficiency and limit toxicity, which we did not address in our study [20,21].
14
15 Finally, we did not have comparative data on symptomatic/biochemical response or
16
17 quality of life after the above treatments in these patients. Prospective studies, preferably
18
19 with stratification of cohorts for tracer avidity and utilizing (177)Lu-DOTATATE as the
20
21 current standard of treatment for PRRT, are required to address these limitations and to
22
23 confirm or refute our conclusions.
24
25
26
27
28
29
30
31

32 **Conclusion**

33
34
35
36 This is the first comparative study between radionuclide treatments for patients with
37
38 metastatic/progressive PGLs and PCCs. These patients are usually studied as a group in
39
40 most studies. Our study has shown superiority of PRRT compared to (131)I-MIBG
41
42 treatment in these patients, with a pronounced effect when comparing PGL patients
43
44 alone. Comparative data and results in our study seem to rely mostly on patients with
45
46 progressive/malignant PGLs. Although the mainstream therapy for progressive/malignant
47
48 PCCs is (131)I-MIBG, there might be a benefit from PRRT treatment as well. This
49
50 should be addressed in future prospective trials.
51
52
53
54
55
56
57
58
59
60

References

1. Fitzgerald PA, Goldsby RE, Huberty JP, et al.: Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG). *Ann N Y Acad Sci* 2006;1073:465-490.
2. Scholz T, Eisenhofer G, Pacak K, et al.: Clinical review: Current treatment of malignant pheochromocytoma. *J Clin Endocrinol Metab* 2007;92:1217-1225.
3. Bourcier ME, Vinik AI: Sunitinib for the treatment of metastatic paraganglioma and vasoactive intestinal polypeptide-producing tumor (VIPoma). *Pancreas* 2013;42:348-352.
4. Venkatesan AM, Locklin J, Lai EW, et al.: Radiofrequency ablation of metastatic pheochromocytoma. *J Vasc Interv Radiol* 2009;20:1483-1490.
5. Gedik GK, Hoefnagel CA, Bais E, Olmos RA: 131I-MIBG therapy in metastatic pheochromocytoma and paraganglioma. *Eur J Nucl Med Mol Imaging* 2008;35:725-733.
6. Tenenbaum F, Schlumberger M, Lumbroso J, Parmentier C: Beneficial effects of octreotide in a patient with a metastatic paraganglioma. *Eur J Cancer* 1996;32A:737.
7. Gulenchyn KY, Yao X, Asa SL, et al.: Radionuclide therapy in neuroendocrine tumours: a systematic review. *Clin Oncol (R Coll Radiol)* 2012;24:294-308.
8. Forrer F, Riedweg I, Maecke HR, Mueller-Brand J: Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma. *Q J Nucl Med Mol Imaging* 2008;52:334-340.
9. V. Prasad, C. Zachert, C. Schuchardt, et al.: Peptide receptor radionuclide therapy (PRRT) for progressive, somatostatin receptor positive pheochromocytoma/paraganglioma. *J Nucl Med* 2008.
10. Puranik AD, Kulkarni HR, Singh A, Baum RP: Peptide receptor radionuclide therapy with (90)Y/ (177)Lu-labelled peptides for inoperable head and neck paragangliomas (glomus tumours). *Eur J Nucl Med Mol Imaging* 2015;42:1223-1230.
11. Spetz J, Dalmo J, Nilsson O, et al.: Specific binding and uptake of 131I-MIBG and 111In-octreotide in metastatic paraganglioma--tools for choice of radionuclide therapy. *Horm Metab Res* 2012;44:400-404.
12. Gonias S, Goldsby R, Matthay KK, et al.: Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. *J Clin Oncol* 2009;27:4162-4168.
13. Rufini V, Calcagni ML, Baum RP: Imaging of neuroendocrine tumors. *Semin Nucl Med* 2006;36:228-247.
14. Zovato S, Kumanova A, Dematte S, et al.: Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in individuals with neck or mediastinal paraganglioma (PGL). *Horm Metab Res* 2012;44:411-414.
15. Chen L, Li F, Zhuang H, et al.: 99mTc-HYNIC-TOC scintigraphy is superior to 131I-MIBG imaging in the evaluation of extraadrenal pheochromocytoma. *J Nucl Med* 2009;50:397-400.

16. Koopmans KP, Jager PL, Kema IP, et al.: ¹¹¹In-octreotide is superior to ¹²³I-metaiodobenzylguanidine for scintigraphic detection of head and neck paragangliomas. *J Nucl Med* 2008;49:1232-1237.
17. Tenenbaum F, Lumbroso J, Schlumberger M, et al.: Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma. *J Nucl Med* 1995;36:1-6.
18. Treglia G, Giovanella L: Could ⁶⁸Ga-somatostatin analogues replace other PET tracers in evaluating extra-adrenal paragangliomas? *Eur J Nucl Med Mol Imaging* 2013;40:1797-1799.
19. Jalil ND, Pattou FN, Combemale F, et al.: Effectiveness and limits of preoperative imaging studies for the localisation of pheochromocytomas and paragangliomas: a review of 282 cases. French Association of Surgery (AFC), and The French Association of Endocrine Surgeons (AFCE). *Eur J Surg* 1998;164:23-28.
20. Madsen MT, Bushnell DL, Juweid ME, et al.: Potential increased tumor-dose delivery with combined ¹³¹I-MIBG and ⁹⁰Y-DOTATOC treatment in neuroendocrine tumors: a theoretic model. *J Nucl Med* 2006;47:660-667.
21. Frilling A, Weber F, Saner F, et al.: Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors. *Surgery* 2006;140:968-976; discussion 976-967.

1
2
3 Figure legends
4
5
6
7

8 Figure 1
9

10 Kaplan Meier Curves comparing Overall Survival, Progression Free Survival and Event
11 Free Survival between patients with Paragangliomas and Pheochromocytomas treated
12 with a) (131)I-MIBG vs PRRT and b) (131)I-MIBG vs (90)Y-DOTATATE.
13
14

15 (* p<0.05)
16
17

18
19
20
21
22 Figure 2
23

24 Kaplan Meier Curves comparing Overall Survival, Progression Free Survival and Event
25 Free Survival only in patients with Paragangliomas treated with a) (131)I-MIBG vs
26 PRRT and b) (131)I-MIBG vs (90)Y-DOTATATE.
27
28
29

30 (* p<0.05)
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1 Characteristics of patients treated with radionuclide therapy

| Case | Age | Sex | Tumor | Genetic Testing | Metastatic at diagnosis | Extent of Disease prior to radionuclide treatment | Clinically Functioning Tumor | Mitosis index |
|------|-----|-----|-------|-----------------|-------------------------|---|------------------------------|----------------------|
| 1 | 56 | M | Phaeo | - | No | Liver | Yes | N/A |
| 2 | 71 | F | Para | - | Yes | Liver | Yes | <1%MIB-1 staining |
| 3 | 41 | M | Para | - | No | Lungs, Liver, Lymph nodes | No | 3 mitoses per 10hpf |
| 4 | 39 | M | Para | SDH-B | Yes | Bones | No | N/A |
| 5 | 7 | F | Para | - | No | Liver, Lymph Nodes | Yes | N/A |
| 6 | 56 | F | Para | - | Yes | Bones | Yes | 1-5% MIB-1 staining |
| 7 | 43 | M | Phaeo | - | Yes | Bones | No | N/A |
| 8 | 59 | M | Phaeo | - | No | Liver, Bone | Yes | N/A |
| 9 | 51 | F | Phaeo | - | Yes | N/A | No | N/A |
| 10 | 63 | M | Phaeo | - | No | Lung, Lymph nodes | Yes | 10% Ki-67 staining |
| 11 | 49 | F | Para | SDH-B | Yes | Liver, Bone, Lymph Nodes | Yes | N/A |
| 12 | 29 | M | Para | - | No | Lungs, Bone, Liver, Lymph Nodes | Yes | N/A |
| 13 | 65 | M | Para | - | No | Bones | No | 15-20% staining |
| 14 | 57 | M | Para | - | Yes | Bones, Lymph nodes | No | 30% Ki-67 staining |
| 15 | 44 | F | Para | - | No | Bones | Yes | N/A |
| 16 | 40 | M | Para | SDH-B | Yes | Bones, Liver | Yes | 50% Ki-67 staining |
| 17 | 42 | F | Para | - | No | *, Bones | No | 1% MIB-1 staining |
| 18 | 35 | M | Para | SDH-B | Yes | Lymph nodes, Soft tissue | Yes | N/A |
| 19 | 68 | F | Phaeo | - | No | Lung, Liver, Lymph nodes | No | 10% MIB-1 staining |
| 20 | 29 | F | Para | SDH-B | Yes | Liver, Lymph nodes | No | 5-10% MIB-1 staining |
| 21 | 36 | F | Para | - | No | Bones | Yes | <5% Ki67 staining |
| 22 | 52 | F | Phaeo | - | No | Lungs, Soft tissue, Intraperitoneal, Liver, bones | Yes | N/A |

M= Male, F= Female, Para= Paraganglioma, Phaeo= Pheochromocytoma, N/A= non available, SDH-B= Succinate dehydrogenase B

* Treatment due to incomplete resection (inoperable) / Progression. Bone metastasis developed during follow-up.

Table 2 Radionuclide and additional treatment to patients with progressive Paragangliomas/Phaeochromocytomas.

| Case | Treatment | Treatment cycles | Total Number of Treatments | Cumulative Activity (MBq) | Somatostatin analogue treatment | Additional Treatment |
|------|--------------------------------------|------------------|----------------------------|---------------------------|---------------------------------|---|
| 1 | (131)I-MIBG | 1 | 3 | 16319 | No | Chemotherapy (oxaliplatin capecitabin) |
| 2 | (131)I-MIBG | 1 | 1 | 3200 | No | - |
| 3 | Comb((131)I-MIBG/(90)Y-DOTATATE) | 3 | 8 | 25644 | Yes | External Radiotherapy |
| 4 | (90)Y-DOTATATE | 1 | 3 | 7780 | No | Chemotherapy (CVD) |
| 5 | (131)I-MIBG | 1 | 3 | 15436 | No | - |
| 6 | (90)Y-DOTATATE | 1 | 3 | 3600 | No | Samarium Nuclide Therapy |
| 7 | (131)I-MIBG | 1 | 5 | 13000 | No | - |
| 8 | (131)I-MIBG | 1 | 3 | 22779 | No | Chemotherapy (CVD) |
| 9 | (131)I-MIBG | 1 | 3 | N/A | No | - |
| 10 | (131)I-MIBG | 3 | 10 | 66436 | No | External Radiotherapy |
| 11 | (177)Lu-DOTATATE | 1 | 3 | N/A | No | External Radiotherapy, Chemotherapy (CVD) |
| 12 | Comb ((131)I-MIBG, (177)Lu-DOTATATE) | 2 | 4 | 28400 | No | Extrenal Radiotherapy |
| 13 | (131)I-MIBG | 1 | 3 | 16201 | No | Extrenal Radiotherapy, Chemotherapy |
| 14 | (90)Y-DOTATATE | 2 | 5 | 14621 | Yes | - |
| 15 | (131)I-MIBG | 1 | 3 | 6323 | No | - |
| 16 | (131)I-MIBG | 2 | 4 | 14917 | Yes | Metastasectomy, External Radiotherapy, Chemotherapy (cisplatin) |
| 17 | (90)Y-DOTATATE | 1 (3)* | 4 | 5680 (11361) | No | Metastasectomy |
| 18 | (90)Y-DOTATATE | 1 | 3 | 9177 | No | - |
| 19 | (131)I-MIBG | 1 | 3 | 15592 | No | Chemotherapy (CVD) |
| 20 | (90)Y-DOTATATE | 1 | 3 | 9427 | Yes | - |
| 21 | (90)Y-DOTATATE | 2 | 6 | 17717 | No | Radiotherapy |
| 22 | (90)Y-DOTATATE | 1 | 1 | 7256 | No | - |

N/A: Not Available, CVD: Cisplatin, Vinblastine, Dacarbazine Chemotherapy

*Patient initially treated for locally advanced symptomatic disease. Second and 3rd single treatment cycles were given for symptom palliation and not for progression of disease.

Table 3 Therapeutic outcomes in patients with PCCs and PGLs

| All patients | (131)I-MIBG | PRRT | P value (compared to (131)I-MIBG) | (90)Y- DOTATATE | P value (compared to (131)I-MIBG) |
|---|------------------|--------------|---|--------------------|---|
| Overall Survival (months) | 41.2±10.4 | 60.8±11.1 | 0.09 | 65.8±12.2 | 0.08 |
| Progression Free Survival (months) | 20.6±3.4 | 38.5±9.4 | 0.10 | 43.2±10.8 | 0.04 * |
| Event Free Survival (months) | 22±5 | 17.9±2.8 | 0.39 | 18.9±3 | 0.54 |
| Response to Treatment (Non progressive disease) | 10/16 (62.5%) | 13/13 (100%) | 0.013 * | 11/11 (100%) | 0.021* |

* P statistically significant

Table 4 Therapeutic outcomes in patients with PGLs

| PGL patients | (131)I-MIBG | PRRT | P value (compared to (131)I-MIBG) | (90)Y- (DOTATOC) | P value (compared to (131)I- MIBG) |
|---|--------------|--------------|---|---------------------|---|
| Overall Survival (months) | 22.8±6.3 | 60.8±11.1 | 0.012 * | 65.8±12.2 | 0.011 * |
| Progression Free Survival (months) | 14.4±2.9 | 38.5±9.4 | 0.018 * | 43.2±10.8 | 0.007 * |
| Event Free Survival (months) | 9.2±2.9 | 17.9±2.8 | 0.042* | 18.9±3 | 0.022 * |
| Response to Treatment (Non progressive disease) | 4/8 (50%) | 13/13 (100%) | 0.005 * | 11/11 (100%) | 0.008 * |

*P statistically significant

Table 5 Haematological and Renal complication in patients with metastatic paragangliomas and pheochromocytomas.

| Case | Treatment | Renal toxicity | Cause of toxicity | Haematological Toxicity | Cause of toxicity |
|------|--------------------------------------|---------------------|----------------------------------|--|--|
| 1 | (131)I-MIBG | - | N/A | Neutropenia (Grade 1) | Chemotherapy for bowel cancer |
| 2 | (131)I-MIBG | Grade not available | Renal obstruction from tumor | Thrombocytopenia (Grade 1), Anaemia (Grade 3) | Radionuclide treatment |
| 3 | Comb((131)I-MIBG/(90)Y-DOTATATE | Grade 3 | Radionuclide treatment | Neutropenia (Grade 2), Lymphocytopenia (Grade 4) | Radionuclide treatment |
| 4 | (90)Y-DOTATATE | - | N/A | Neutropenia (Grade 3), Thrombocytopenia (Grade 4) | Chemotherapy (CVD) |
| 5 | (131)I-MIBG | - | N/A | - | N/A |
| 6 | (90)Y-DOTATATE | Grade 1 | Radionuclide treatment | Anaemia (Grade 2), Thrombocytopenia (Grade 3) | Radionuclide treatment, Bone marrow tumor infiltration |
| 7 | (131)I-MIBG | - | N/A | - | N/A |
| 8 | (131)I-MIBG | - | N/A | Leukopenia (Grade 2) | Chemotherapy (CVD) |
| 9 | (131)I-MIBG | - | N/A | - | N/A |
| 10 | (131)I-MIBG | Grade 1 | Radionuclide treatment | Leukopenia (Grade 2), Anaemia (Grade 2) | Radionuclide treatment |
| 11 | (177)Lu-DOTATATE | - | N/A | Thrombocytopenia (Grade 2) | Radionuclide treatment |
| 12 | Comb [(131)I-MIBG, (177)Lu-DOTATATE] | Grade not available | NSAIDS after metastatic fracture | - | N/A |
| 13 | (131)I-MIBG | - | N/A | Anaemia (Grade 2), Leukopenia (Grade 2) Thrombocytopenia (Grade 2) | Monosomy 7 |
| 14 | (90)Y-DOTATATE | - | N/A | - | N/A |
| 15 | (131)I-MIBG | - | N/A | - | N/A |
| 16 | (131)I-MIBG | - | N/A | - | N/A |
| 17 | (90)Y-DOTATATE | Grade 2 | Radionuclide treatment | - | N/A |
| 18 | (90)Y-DOTATATE | - | N/A | - | N/A |
| 19 | (131)I-MIBG | - | N/A | - | N/A |
| 20 | (90)Y-DOTATATE | - | N/A | - | N/A |
| 21 | (90)Y-DOTATATE | - | N/A | - | N/A |
| 22 | (90)Y-DOTATATE | - | N/A | - | N/A |

N/A: Non Applicable

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1

111x134mm (300 x 300 DPI)




Figure 2

111x134mm (300 x 300 DPI)